Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report

Share this page:

Title

Subject

Description

BNT162b2 is a nucleoside-modified RNA vaccine expressing the full-length prefusion spike glycoprotein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In a randomized, placebo-controlled clinical trial involving approximately 44,000 participants, immunization conferred 95% efficacy against coronavirus disease 2019 (Covid-19).

Creator

Date Last Updated (Year-Month-Day)

2021-02-17

Type

Publication

Citation

Liu, Yang, Jianying Liu, Hongjie Xia, Xianwen Zhang, Camila R. Fontes-Garfias, Kena A. Swanson, Hui Cai, Ritu Sarkar, Wei Chen, Mark Cutler, David Cooper, Scott C. Weaver, Alexander Muik, Ugur Sahin, Kathrin U. Jansen, Xuping Xie, Philip R. Dormitzer, and Pei-Yong Shi. 2021. "Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report." New England Journal of Medicine.

Accessibility

Free online on NEJM.

URL

https://www.nejm.org/doi/full/10.1056/NEJMc2102017

Read Online

https://www.nejm.org/doi/full/10.1056/NEJMc2102017

Click for External Resource

https://www.nejm.org/doi/full/10.1056/NEJMc2102017

*This link may link to a hosted zip file or an external resource. Zip files will download automatically. Other links will open in a new window.

Item Type:

Publication

Collection

Discover

Citation for this page

Liu, Yang, Jianying Liu, Hongjie Xia, Xianwen Zhang, Camila R. Fontes-Garfias, Kena A. Swanson, Hui Cai, Ritu Sarkar, Wei Chen, Mark Cutler, David Cooper, Scott C. Weaver, Alexander Muik, Ugur Sahin, Kathrin U. Jansen, Xuping Xie, Philip R. Dormitzer, and Pei-Yong Shi. , “Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report,” NETEC Resource Library, accessed March 3, 2021, https://repository.netecweb.org/items/show/1489.

Terms of Use

By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.